Skip to content
Calculator
Evidence: MediumPeptideResearch ChemicalEndogenous gut hormoneGLP-1 + glucagon receptor co-agonistNot a medicine

Oxyntomodulin

The gut hormone that inspired the GLP-1/glucagon dual agonists

Oxyntomodulin is a natural gut hormone made from the same gene as glucagon and released after eating. It activates both the GLP-1 receptor and the glucagon receptor, and in small human trials it reduced appetite and food intake, raised energy expenditure, and produced modest weight loss. It is the blueprint for dual agonists such as survodutide and mazdutide.

Used in human trials: 3.0 pmol/kg/min, Single infusion, Intravenous (Research: appetite in healthy volunteers) Details ↓

Overview

What is it?

Oxyntomodulin is a product of the glucagon gene made in the lower intestine and released after meals. It acts on both the GLP-1 receptor and the glucagon receptor, a combination drug designers later copied. Its plasma half-life is about 12 minutes.

London studies in the 2000s tested it for appetite. An infusion in healthy volunteers cut food intake at a buffet by 19% and suppressed the hunger hormone ghrelin. In overweight and obese volunteers, self-injection three times a day before meals for four weeks led to 2.3 kg of weight loss against 0.5 kg on saline, and another trial found it raised activity-related energy expenditure by 26% while reducing intake. Given with PYY, it cut intake by 43%.

A 2018 study found native oxyntomodulin increased glucose-dependent insulin secretion in obese people with and without type 2 diabetes, comparable to liraglutide and independent of weight loss. A 2019 trial infused GLP-1, oxyntomodulin and PYY together for four weeks and found greater weight loss and better glucose control than saline.

Rat work explains the division of labour: an oxyntomodulin analogue's rise in energy expenditure disappeared without the glucagon receptor but not without the GLP-1 receptor. In people, oxyntomodulin secretion is impaired in type 2 diabetes and rises more than tenfold after gastric bypass, and larger post-meal responses after surgery predicted greater weight loss.

As a blood measurement it is still settling. Commercial glucagon tests cross-react with it, which is why a 2026 interlaboratory study validated a mass-spectrometry assay. Small studies link fasting levels to visceral fat in obesity but not in polycystic ovary syndrome, and lower levels to diabetes after pancreatitis.

Native oxyntomodulin lasts minutes and was never developed as a medicine. Its dual action is the template for longer-acting GLP-1/glucagon co-agonists such as survodutide and mazdutide, which have their own entries.

−19%
Buffet intake on infusion
healthy volunteers · PMID 14557443
>10×
Rise after gastric bypass
impaired in type 2 diabetes · PMID 27322465
~12 min
Plasma half-life
why it was never a drug · PMID 3147901
Science

Mechanism of Action

Oxyntomodulin is a glucagon-gene product from intestinal L-cells that activates both the GLP-1 receptor and the glucagon receptor.

🍽️

Appetite (GLP-1 receptor)

Infusions reduced food intake and suppressed ghrelin; it is co-secreted with GLP-1 after meals.

🔥

Energy expenditure (glucagon receptor)

In rats an analogue raised energy expenditure only when the glucagon receptor was active.

🩸

Insulin secretion

Native oxyntomodulin increased glucose-dependent insulin secretion, comparable to liraglutide in type 2 diabetes.

Evidence

Published Research

Studies of oxyntomodulin, from their PubMed abstracts.

Human2005

Four weeks of injections in obesity

Subcutaneous oxyntomodulin three times daily before meals for 4 weeks reduced body weight by 2.3 kg versus 0.5 kg on saline (P = 0.0106), with energy intake 25-35% lower at study meals.

PMID: 16046306
Human2003

Appetite in healthy volunteers

IV oxyntomodulin reduced buffet energy intake by 19.3% and 12-hour intake by 11.3%, lowered hunger scores and suppressed preprandial ghrelin, without nausea.

PMID: 14557443
Human2006

Energy expenditure

In overweight and obese volunteers, oxyntomodulin reduced meal intake by 17.3%, raised activity-related energy expenditure by 26.2% and total energy expenditure by 9.4%, without changing resting expenditure.

PMID: 16619056
Human2018

Insulin secretion in obesity and type 2 diabetes

Native oxyntomodulin at 3.0 pmol/kg/min increased insulin secretion and blunted glucose excursions in obese subjects with and without type 2 diabetes, comparable to liraglutide.

PMID: 29545266
Human2010

Added to PYY3-36

Co-infusion of PYY3-36 and oxyntomodulin reduced energy intake by 42.7% versus saline, significantly more than either hormone alone.

PMID: 20357366
Human2019

GLP-1, oxyntomodulin and PYY together

A 4-week infusion of the three hormones produced weight loss of 4.4 kg versus 2.5 kg with saline and a larger fall in fructosamine, and was well tolerated.

PMID: 31177183
Human1988

Pharmacokinetics

In six volunteers, synthetic oxyntomodulin had a plasma half-life of 12 minutes, reduced pentagastrin-stimulated gastric acid secretion, and slightly raised insulin and C-peptide.

PMID: 3147901
Human2016

Impaired in diabetes, up tenfold after bypass

Mass-spectrometry profiling found oxyntomodulin secretion impaired in type 2 diabetes and raised more than tenfold after gastric bypass; it is co-secreted with GLP-1 and inactivated by the same enzyme, DPP-4.

PMID: 27322465
Human2020

Predicting bariatric outcomes

After gastric bypass and sleeve gastrectomy, larger post-meal oxyntomodulin and glicentin responses predicted greater weight loss and a shift toward lower energy-density foods; GLP-1, PYY and ghrelin did not.

PMID: 32016415
Human2024

Lower in glucose responders

In a randomised trial of a ketone drink, people whose glucose fell most had a lower oxyntomodulin response than on placebo, while GLP-1, glicentin and glucagon did not differ.

PMID: 38901179
Human2021

Mediterranean versus vegetarian meal

In overweight people with type 2 diabetes, a Mediterranean meal raised post-meal GLP-1 and oxyntomodulin more than a high-fibre vegetarian meal and gave a lower glucose profile.

PMID: 32926502
Human2026

Not changed by running

Moderate-intensity running increased fullness and lowered later energy intake but did not change circulating oxyntomodulin, which did not track appetite.

PMID: 41833829
Human2021

Food-cue brain responses

In a brain imaging study, fasting oxyntomodulin and glicentin levels were associated with activation of reward areas and the hypothalamus when people viewed highly desirable food.

PMID: 33417264
Human2025

A marker of visceral fat?

In adults with obesity, fasting oxyntomodulin was highest in the more advanced group and correlated with visceral fat and insulin resistance; the authors call it preliminary.

PMID: 41408640
Human2025

No link in polycystic ovary syndrome

In women with polycystic ovary syndrome, oxyntomodulin correlated with age but not with BMI, waist, visceral fat or insulin, and did not change after 60 days of metformin.

PMID: 40532052
Human2020

Diabetes after pancreatitis

Oxyntomodulin was lower in new-onset diabetes after acute pancreatitis than in type 2 diabetes or healthy controls, suggesting it could help tell them apart.

PMID: 32463621
Human2022

What drives its levels

In 58 healthy people, PYY explained 60% of the variation in oxyntomodulin; after acute pancreatitis, cholecystokinin was the strongest associated factor.

PMID: 36395403
In Vitro2026

Measuring it properly

An interlaboratory study validated an immuno-LC-MS/MS assay for glucagon and oxyntomodulin and found commercial glucagon immunoassays cross-react with oxyntomodulin.

PMID: 42400596
Dosing

Dosing Data

Oxyntomodulin is not a medicine. Research studies infused it at 3.0 pmol/kg/min or had volunteers self-inject before meals.

These are research doses. Native oxyntomodulin lasts minutes; the long-acting co-agonists derived from it have their own entries.
ProtocolDoseFrequencyDurationRoute
Research: appetite in healthy volunteers Human studyPMID 145574433.0 pmol/kg/minSingle infusionOne study sessionIntravenous
Research: insulin secretion in obesity and type 2 diabetes Human studyPMID 295452663.0 pmol/kg/minSingle infusionCrossover sessionsIntravenous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Research infusion rates
Oxyntomodulin has been dosed by weight as an infusion rate in picomoles per kilogram per minute, in research units only.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no label and no published test that says what forms or vial sizes Oxyntomodulin is sold in. A vial's own label is a seller's claim, not a source.

Mixing a vial: a worked example

No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: intravenous). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.

Source: the route and amount of each dose row in Dosing Data below.

Storage before and after mixing

Unknown: no label or published stability study on file says how to store Oxyntomodulin, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Oxyntomodulin stays intact once mixed.

How it is taken

As it was given in human studies: Intravenous (Single infusion; Research: appetite in healthy volunteers).

For injection technique, sites and needle disposal, see the mixing guide.

Source: Used in human trials: the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of 12 minutes in plasma during infusion in six volunteers (PMID 3147901). After about five half-lives almost none is left.

How long the doses were given: Research: appetite in healthy volunteers: One study session; Research: insulin secretion in obesity and type 2 diabetes: Crossover sessions.

When effects appear: unknown; no source on this page gives a time to effect for Oxyntomodulin. Results reported in the studies are under Published Research.

Source: half-life: PMID 3147901; Used in human trials, the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: No nausea during the 2003 infusion study; The 4-week triple-hormone infusion was well tolerated. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Oxyntomodulin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the short trials above”).

Interactions

Unknown: a PubMed search for human interaction studies of Oxyntomodulin (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Oxyntomodulin products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Oxyntomodulin's expected mass, 4,422.0 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: Research Chemical (Not approved as a medicine). Sport: Prohibited (S0 catch-all).

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the short trials above.

● No nausea during the 2003 infusion study
● The 4-week triple-hormone infusion was well tolerated

Contraindications & Cautions

There is no label.

● Not approved for any use
Questions

Frequently Asked Questions

?What is oxyntomodulin?

A natural gut hormone made from the glucagon gene and released after meals. It activates both GLP-1 and glucagon receptors.

?Does oxyntomodulin cause weight loss?

In a 4-week trial of injections three times a day, volunteers lost 2.3 kg against 0.5 kg on saline. It reduces appetite and, in one study, raised activity-related energy expenditure.

?Why isn't oxyntomodulin a drug?

It lasts about 12 minutes in blood, so drug makers built longer-acting molecules with the same dual action.

?How does it relate to survodutide and mazdutide?

Those are synthetic GLP-1/glucagon dual agonists designed to copy oxyntomodulin's two-receptor action while lasting much longer.

?Does oxyntomodulin explain weight loss after bariatric surgery?

It may contribute. Levels rise more than tenfold after gastric bypass, and in one study larger post-meal oxyntomodulin and glicentin responses predicted greater weight loss, while GLP-1, PYY and ghrelin did not.

?Can oxyntomodulin be measured accurately?

It is difficult: commercial glucagon immunoassays cross-react with it. A 2026 interlaboratory study validated a mass-spectrometry method for measuring both separately.

Bibliography

References

  1. [other] PubChem CID 16144019, Oxyntomodulin: formula C192H295N59O60S, molecular weight 4422. Read October 3, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/16144019
  2. [fda] FDA. Drugs@FDA (openFDA): no application on record for oxyntomodulin. Read October 3, 2026.
  3. [clinical-trial] Wynne K, et al. "Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial." Diabetes, 2005;54(8):2390-5. PMID: 16046306.
  4. [clinical-trial] Cohen MA, et al. "Oxyntomodulin suppresses appetite and reduces food intake in humans." J Clin Endocrinol Metab, 2003;88(10):4696-701. PMID: 14557443.
  5. [clinical-trial] Wynne K, et al. "Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial." Int J Obes (Lond), 2006;30(12):1729-36. PMID: 16619056.
  6. [clinical-trial] Shankar SS, et al. "Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes." Diabetes, 2018;67(6):1105-1112. PMID: 29545266.
  7. [clinical-trial] Field BC, et al. "PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans." Diabetes, 2010;59(7):1635-9. PMID: 20357366.
  8. [clinical-trial] Behary P, et al. "Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study." Diabetes Care, 2019;42(8):1446-1453. PMID: 31177183.
  9. [pubmed] Schjoldager BT, et al. "Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man." Eur J Clin Invest, 1988;18(5):499-503. PMID: 3147901.
  10. [pubmed] Wewer Albrechtsen NJ, et al. "Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma." EBioMedicine, 2016;7:112-20. PMID: 27322465.
  11. [pubmed] Nielsen MS, et al. "Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss." J Clin Endocrinol Metab, 2020;105(4). PMID: 32016415.
  12. [pubmed] Liu Y, et al. "Response to lowering plasma glucose is characterised by decreased oxyntomodulin: Results from a randomised controlled trial." Diabetes Metab Syndr, 2024;18(6):103052. PMID: 38901179.
  13. [pubmed] Di Mauro A, et al. "The Mediterranean diet increases glucagon-like peptide 1 and oxyntomodulin compared with a vegetarian diet in patients with type 2 diabetes: A randomized controlled cross-over trial." Diabetes Metab Res Rev, 2021;37(6):e3406. PMID: 32926502.
  14. [pubmed] Jin Z, et al. "Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy men and women." Appetite, 2026;222:108541. PMID: 41833829.
  15. [pubmed] Perakakis N, et al. "Fasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of reward- and attention-related brain centres in response to visual food cues in adults with obesity: A cross-sectional functional MRI study." Diabetes Obes Metab, 2021;23(5):1202-1207. PMID: 33417264.
  16. [pubmed] Zwierz M, et al. "Preliminary evaluation of oxyntomodulin as a biomarker for metabolic risk stratification in adults with obesity." J Transl Med, 2025;23(1):1400. PMID: 41408640.
  17. [pubmed] Damasceno RC, et al. "Dissociation of plasma oxyntomodulin levels from anthropometric measures and metabolic markers in women with polycystic ovary syndrome." Arch Endocrinol Metab, 2025;69(3):e240451. PMID: 40532052.
  18. [pubmed] Bharmal SH, et al. "Oxyntomodulin May Distinguish New-Onset Diabetes After Acute Pancreatitis From Type 2 Diabetes." Clin Transl Gastroenterol, 2020;11(2):e00132. PMID: 32463621.
  19. [pubmed] Bharmal SH, et al. "Factors Affecting the Circulating Levels of Oxyntomodulin in Health and After Acute Pancreatitis." Pancreas, 2022;51(7):774-783. PMID: 36395403.
  20. [pubmed] Moradian A, et al. "Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research." Clin Chem, 2026. PMID: 42400596.
  21. [pubmed] Scott R, et al. "Oxyntomodulin analogue increases energy expenditure via the glucagon receptor." Peptides, 2018;104:70-77. PMID: 29680267.

Sources & Citations

Studies were read from their PubMed abstracts; oxyntomodulin has no label. Read October 7, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-19